Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026

Structure Therapeutics (GPCR) Stock May Be A Bargain Given Its Asset Base

Structure Therapeutics (NasdaqGM:GPCR) Stock Forecast & Analyst Predictions

Structure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In Focus

Structure Therapeutics (GPCR) CMO sells shares under preset plan

VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’

Structure Therapeutics (GPCR): Will Repeat Dosing Confirm Its 3.3% Weight-Loss Signal?

Structure Therapeutics Reports Up to 16.2% Weight Loss in Aleniglipron Trial

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

Structure Therapeutics falls on obesity drug data (GPCR:NASDAQ)

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?

Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now

H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR)

Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at